Pulse Biosciences, Inc. (PLSE) - Stock Analysis
Last updated: Mar 9, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
High-impact AFib feasibility data and FDA IDE for NANOPULSE-AF, plus an upcoming Q4 call, have driven a ~66% 21-day surge and clear breakout; with minimal revenue and cash-burn risk this is a speculative but genuinely news-driven short-term hot momentum name.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High cash burn ⢠Strong liquidity ⢠Extreme valuation PLSE shows strong liquidity and low leverage but faces material cash burn, sustained large operating losses, negligible revenue, and extreme valuation multiples implying significant downside risk.
Price Behavior
Key Price Behavior Insights: ⢠Below SMA ⢠Oversold RSI ⢠Volatile swings Support Level: $13.69 Resistance Level: $20â$25 ($20.85 SMA; prior high $25.46) Price is below its last month SMA (~$20.85) with an oversold RSI (~29.5), suggesting downside bias until a reclaim above the SMA despite a nearby support at $13.69 and resistance cluster near $20â$25.
Sentiment & News
Key News Insights: ⢠Clinical success ⢠Earnings beat ⢠Investor engagement Pulse Biosciences posted strong first-in-human nPulse cardiac results (up to 100% procedural success), beat Q4 revenue and narrowed EPS loss, announced investor presentations and new hires, and logged an insider sale.
AI Summary
Pulse's investment thesis has shifted from speculative long-term optionality to a clinical-data-driven, near-term binary: successful IDE/pivotal readouts and timely payer wins are now the primary drivers of valuation upside, while trial execution risk, limited ~1â2 year cash runway, and likely dilutive financing are the key downside triggers. Investors should therefore treat PLSE as a trial-timing and reimbursement binaryâposition size and timing should hinge on confidence in enrollment/execution and the company's ability to secure early coverage.
Description
Pulse Biosciences, Inc. is a bioelectric medicine company that develops the CellFX System, a console-based platform that delivers nanosecond electrical pulses (Nano-Pulse Stimulation) to non-thermally remove targeted cells while sparing surrounding non-cellular tissue. The company was incorporated in 2014, changed its name from Electroblate, Inc. to Pulse Biosciences in December 2015, and is headquartered in Hayward, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 18 | Feb 25 | PLSE | Pulse Biosciences, Inc. | High-impact AFib feasibility data and FDA IDE for NANOPULSE-AF, plus an upcoming Q4 call, have driven a ~66% 21-day surge and clear breakout; with minimal revenue and cash-burn risk this is a speculative but genuinely news-driven short-term hot momentum name. | Closed | -24.6% |
| Feb 11 | Feb 18 | PLSE | Pulse Biosciences, Inc. | FDA IDEs for NANOPULSEâAF and nPulse 360 EP plus strong firstâinâhuman ablation data (150 patients, presented 2026â02â05) triggered a ~75% threeâday jump and price ~55% above its 21âday SMA, making PLSE a highâvolatility clinicalâcatalyst momentum trade into the 2026â02â19 earnings update. | Closed | +0.8% |